The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 11, 2025
Filed:
Jan. 08, 2020
Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);
Zhen Li, San Diego, CA (US);
Dongxu Shu, Madison, WI (US);
Anthony Nicholas, Oregon, WI (US);
Rui Zhu, San Diego, CA (US);
Jeffrey Carlson, Madison, WI (US);
So Wong, Oregon, WI (US);
Xiaokai Li, Middleton, WI (US);
Erich Altenhofer, Madison, WI (US);
Matthew Fowler-Watters, Madison, WI (US);
Bo Chen, Scarsdale, NY (US);
Arrowhead Pharmaceuticals, Inc., Pasadena, CA (US);
Abstract
The present disclosure relates to RNAi agents, for example, double stranded RNAi agents, able to inhibit HIF-2 alpha (EPAS1) gene expression. Also disclosed are pharmaceutical compositions that include HIF-2 alpha RNAi agents and methods of use thereof. The HIF-2 alpha RNAi agents disclosed herein may be linked or conjugated to targeting ligands (such as compounds that have affinity for integrins, including alpha-v-beta-3 and alpha-v-beta-5 integrins) and pharmacokinetic (PK) enhancers, to facilitate the delivery to cells and tissues, including to clear cell renal cell carcinoma (ccRCC) cells and tumors. Delivery of compositions comprising the HIF-2 alpha RNAi agents in vivo provides for inhibition of HIF-2 alpha gene expression. The HIF-2 alpha RNAi agents can be used in methods of treatment of various diseases and disorders, including ccRCC.